The Interagency Autism Coordinating Committee, the federal body that directs roughly $2 billion in annual autism research funding, was supposed to hold its first public meeting since January on March 19. It didn't happen. HHS cancelled the meeting without explanation, and when asked for comment, went silent.

That might not sound like news. Bureaucratic committees postpone meetings all the time. But this one matters. The IACC isn't advisory in the way most federal panels are. It's congressionally mandated, established in 2006 to coordinate federal autism research across agencies and set priorities for what gets studied and funded. When the IACC says something is a priority, that shapes where grant money flows: which therapies get validation studies, which intervention strategies get longitudinal research, which questions even get asked.

On January 28, HHS announced a complete reconstitution of the committee. All 21 members were new. The scientific and advocacy leadership that historically guided the IACC weren't reappointed. Researchers from major universities, representatives from the Autism Society of America and the Autistic Self Advocacy Network, clinicians with decades of experience were replaced entirely. More than a third of the new members have publicly promoted the long-debunked link between vaccines and autism.

That reconstitution raised questions about whether the current committee even complies with federal statute, which requires IACC membership to include "leading research, advocacy, and service organizations for individuals with autism spectrum disorder." When the panel that sets research priorities is stacked with people whose public positions contradict the scientific consensus, that's not just a personnel change. It's a signal about what kind of research might get prioritized going forward.

The cancelled March 19 meeting was supposed to be the first time the public would see this new committee in action. Dr. Sylvia Fogel, the new panel chair from Harvard Medical School, said it was "postponed" and that the committee is "actively working to reschedule." No timeline was given. HHS didn't respond to press requests for clarification.

What Happens When Scientists Don't Trust the Federal Panel

Over 300 autism researchers weren't willing to wait. The Autism Science Foundation and the Coalition of Autism Scientists announced the formation of an Independent Autism Coordinating Committee, the I-ACC. It includes two former directors of the National Institute of Mental Health, researchers from universities across the country, representatives from the American Academy of Pediatrics and Autism Society of America, and autistic self-advocates. They held their own meeting on March 19, the same day the federal committee was supposed to convene.

That's not symbolic protest. It's a parallel structure. When leading scientists create an independent committee to track autism research priorities because they don't trust the federal one, that's a breakdown in institutional function.

The concern isn't abstract. Federal research funding drives what gets studied. If the IACC shifts priorities toward investigating vaccine safety, a question thoroughly answered by decades of research showing no link between vaccines and autism, that's grant money not going toward early intervention outcomes, genetic research, or support services. The Autism Science Foundation put it plainly: "The committee charged to direct nearly $2 billion in autism research funding must be expected to show up also, without delay."

What This Means for Autism Research Funding

The IACC's statutory role is to develop and annually update a strategic plan for autism research. That plan influences funding decisions across multiple federal agencies: the National Institutes of Health, the Centers for Disease Control and Prevention, the Department of Education, and others. When researchers apply for grants, their proposals get evaluated partly on how well they match IACC priorities.

If those priorities shift away from expanding access to evidence-based therapies and toward relitigating vaccine safety, or away from autistic self-advocacy and toward cure-focused frameworks, that changes what gets funded. Researchers follow the money. If the grant priorities change, so does the research pipeline.

Right now, no one knows what the reconstituted IACC's priorities are. The committee hasn't held a public meeting. The strategic plan hasn't been updated. The fact that the first scheduled meeting got cancelled without explanation doesn't inspire confidence that the process is functioning.

What Families Should Know

If you're a parent or caregiver navigating autism support services, this might feel distant from your day-to-day reality. It's not. Research funding shapes what therapies get validated, what support models get studied, and what practitioners have access to evidence-based protocols. When the committee directing that funding is reconstituted with members whose public positions conflict with the scientific consensus, that matters.

The I-ACC formation is significant because it means the scientific community isn't treating this as routine. Leading researchers don't typically create parallel committees in response to federal personnel changes. That they did suggests this isn't a normal transition.

For now, the questions are basic: Will the federal IACC hold a public meeting? Will it release an updated strategic plan? What priorities will that plan reflect? And will researchers and advocates trust the committee enough to engage with it, or will the I-ACC become the de facto coordinating body that the autism research community listens to?

None of those questions have answers yet. But the fact that they're being asked three months after a committee reconstitution that replaced scientific leadership with vaccine-skeptic voices, and one week after a cancelled meeting with no explanation, tells you where things stand.